Phase I/IIa Study for AZD5335 as monotherapy and in combination with anti-cancer agents in participants with Solid Tumors

Trial Identifier:	D8990C00001
Sponsor:	AstraZeneca
NCTID::	NCT05797168
Start Date:	June 2023
Primary Completion Date:	November 2027
Study Completion Date:	November 2027
Condition:	Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
AU	Melbourne, AU, 3000
US, CA	Duarte, CA, US, 91010
US, CA	La Jolla, CA, US, 92093
US, KY	Louisville, KY, US, 40202
US, MA	Boston, MA, US, 02114
US, OH	Columbus, OH, US, 43201
US, OR	Portland, OR, US, 97239
US, TX	Houston, TX, US, 77030

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company